Prosecution Insights
Last updated: April 19, 2026
Application No. 17/096,655

FABRIC FIBER ARRANGEMENTS FOR CARDIAC IMPLANTS

Final Rejection §103
Filed
Nov 12, 2020
Examiner
WILLSE, DAVID H
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Edwards Lifesciences Innovation (Israel) Ltd.
OA Round
4 (Final)
68%
Grant Probability
Favorable
5-6
OA Rounds
3y 11m
To Grant
80%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
388 granted / 575 resolved
-2.5% vs TC avg
Moderate +13% lift
Without
With
+12.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
40 currently pending
Career history
615
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
49.7%
+9.7% vs TC avg
§102
22.8%
-17.2% vs TC avg
§112
12.1%
-27.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 575 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 83-97, 101, and 110-115 are rejected under 35 U.S.C. 103 as being unpatentable over Gilmore et al., US 9,801,720 B2, cited in the Information Disclosure Statement of November 14, 2023. Figure 4B shows an implant or tether 22 with alternating patterns defined by knots 170 (column 27, lines 34-64), the crosshatched lines at different angles apparently depicting the warp and woof of a knitted fabric, and such a fabric would have been obvious to one of ordinary skill in the art at the effective filing date of the present invention in order to lessen stress concentrations near and along knots 170 (column 1, lines 57-61; column 5, lines 6-7; column 6, lines 1-2 and 25-28; column 44, lines 1-15), to support shear and torsional stresses (column 2, lines 1-3; column 3, lines 8-10; column 4, lines 54-55; column 34, lines 21-26), and to facilitate incorporation of electrically conductive and/or radiopaque wires or fibers (column 12, lines 49-50; column 17, lines 1-2; column 36, line 65, to column 37, line 2; column 46, lines 25-35). Each knot 170 would thus be an instance of a first fabric alternating with instances of an integrally attached second fabric disposed between successive knots 170, with a continuum of angles for first, second, third, and fourth fibers including respective orientations of 45°, 135°, 0°, and 90° relative to a longitudinal axis of tether 22 (MPEP § 2125), and the body portion or tether 22 so formed is configured to be secured along tissue of the heart such that the longitudinal axis lies along the tissue with the alternating pattern alternating along the tissue (Figures 5B-5D, 6C-6E, 8-9, 16A-16C; abstract; column 5, lines 1-7; column 29, line 47, et seq.; column 43, lines 59-61; column 44, lines 11-15; etc.). Regarding claims 84-88, the second fabric is configured to be attached to tissue via a helical screw anchor (Figures 1A-1F, 2A-2B, 3A-3E, 6A, 6C, 8, 12A-12C, 13A-13B, 14A-14B, 15, 22, 23A-23B, 24A-24C; abstract; column 3, lines 43-46 and 57-62; column 24, line 4, et seq.; column 37, lines 9-19; column 39, lines 41-67); because of the sharpened distal end (drawings; column 24, lines 7-9), the helical screw anchor is structurally capable of being driven through the second fabric (instant claim 87; MPEP § 2114), whether or not such was the intended use. The further limitations of claims 89-97 are addressed above (MPEP § 707). Regarding claim 101, polyethylene terephthalate (PET) was well-known in the art at the effective filing date of the present application and would have been obvious from its advantageous properties as to strength, biocompatibility, and so on, with the ordinary practitioner having been left to select a suitable material for the “polymer” or “polymer/metal composite” (e.g., column 12, lines 48-50). Regarding claims 110-111, “first” and “second” instances of fabric are somewhat arbitrary with respect to the limitations of present claim 83; knots 170 have greater strength and lesser lateral compressibility because of their enhanced thickness and tightened state in comparison to the intervening instances (with “first” and “second” being interchanged relative to the discussions above). Regarding claim 112, body portion or tether 22 is physically capable of being secured along a heart valve annulus such that a longitudinal axis of tether 22 lies with the pattern alternating along the annulus, even though such was not the purpose of the implant (MPEP § 2114). Regarding claim 113, the Gilmore et al. system and method additionally comprise tools for securing tether 22 along heart tissue (Figures 5A-5D, 6A-6E, 7, 9; column 1, lines 64-67; column 3, lines 4-14; column 5, line 18, et seq.; column 28, line 43, et seq.). Regarding claims 114 and 115, tensioning a flexible elongate member such as the aforementioned electrically conductive or radiopaque wire or fiber (column 46, lines 25-35) straightens and lengthens body portion 22 by virtue of the innate stress-strain characteristic or elastic modulus of the wire or fiber material. Allowable Subject Matter Claims 98 and 107-109 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Response to Arguments Applicant’s remarks have been considered but are deemed moot in view of the new grounds of rejection, necessitated by the new claims and by the language added to claim 83. Conclusion Applicant’s amendment necessitated the new grounds of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL (MPEP § 706.07(a)). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David H. Willse, whose telephone number is 571-272-4762. The examiner can normally be reached on Monday through Thursday. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor Melanie Tyson can be reached at telephone number 571-272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal. Should you have questions about access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, Applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. /DAVID H WILLSE/ Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Nov 12, 2020
Application Filed
Aug 10, 2023
Non-Final Rejection — §103
Nov 14, 2023
Response Filed
Nov 14, 2023
Response after Non-Final Action
Apr 28, 2024
Response Filed
Aug 27, 2024
Final Rejection — §103
Nov 22, 2024
Request for Continued Examination
Nov 25, 2024
Response after Non-Final Action
Apr 05, 2025
Non-Final Rejection — §103
Jul 09, 2025
Response Filed
Oct 29, 2025
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594159
SEALING MEMBER FOR PROSTHETIC HEART VALVE
2y 5m to grant Granted Apr 07, 2026
Patent 12558238
ARTHROPLASTY INSERT
2y 5m to grant Granted Feb 24, 2026
Patent 12508133
Prosthesis Surface Treatment for Soft Tissue Attachment Thereto
2y 5m to grant Granted Dec 30, 2025
Patent 12502288
PROSTHETIC FOOT WITH REMOVABLE FLEXIBLE MEMBERS
2y 5m to grant Granted Dec 23, 2025
Patent 12496195
SYSTEMS AND METHODS OF A GLENOID COMPONENT
2y 5m to grant Granted Dec 16, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
68%
Grant Probability
80%
With Interview (+12.9%)
3y 11m
Median Time to Grant
High
PTA Risk
Based on 575 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month